What does ER stand for?

Byline: ANI Washington, Oct 20 (ANI): A right mix of estrogen and a selective estrogen receptor modulator (SERM), which blocks the effects of estrogen in breast tissue, can significantly reduce breast cancer risk in menopausal women, say researchers Women in menopause who have symptoms are currently treated with a combination of estrogen plus progestin hormone therapy, however this treatment comes with side effects, including a higher risk of breast cancer caused by the progestin.

They seem to be involved in aromatase expression, generation of estrogens and activation of estrogen receptor alpha (ERalpha) in malignant breast epithelium.

His topics include micronutrients and the evolution of skin pigmentation, weaning and brain development, the conflict between agricultural and ancestral genes, genomic and non-genomic influence at the estrogen receptor, and dietary zootoxins.

The purpose of estrogen receptors is to receive estrogen and allow the body to process the estrogen.

Ophena(tm) is a new-generation selective estrogen receptor modulator (SERM) for postmenopausal vaginal syndrome (PVS), a common condition in postmenopausal women sometimes referred to as vaginal atrophy and characterized by vaginal symptoms such as dryness, irritation and sexual pain.

The test uses antibodies, which brightly color the estrogen receptors if they are present.

Estrogen receptor (ER)-positive breast cancer patients receive so much benefit from estrogen-blocking hormone therapy that undergoing chemotherapy may add little, if any, benefit to their treatment regimens.

Raloxifene is a selective estrogen receptor modulator, specifically developed to maintain beneficial estrogenic activity on bone and lipids and antiestrogenic activity on endometrial and breast tissue.